Today: 27 January 2026
Subscribe
Browse Category

Biotech Industry News 12 November 2025 - 22 December 2025

Zenas BioPharma (ZBIO) Stock Hits a Record High on Dec. 22, 2025 as INDIGO Phase 3 Catalyst Nears — Latest News, Analyst Forecasts, and What’s Next

Zenas BioPharma (ZBIO) Stock Hits a Record High on Dec. 22, 2025 as INDIGO Phase 3 Catalyst Nears — Latest News, Analyst Forecasts, and What’s Next

Zenas BioPharma, Inc. (NASDAQ: ZBIO) is having one of those classic biotech days where the market starts acting like it can see the future. On Monday, December 22, 2025, ZBIO surged roughly 14% and traded around $41.23 by early afternoon Eastern time—after touching a fresh all-time high near $41.67, according to multiple market data reports. MarketBeat The timing isn’t subtle:…
22 December 2025
····
Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Latest News, Analyst Forecasts, and What Comes Next (Dec. 21, 2025)

Amicus Therapeutics (FOLD) Stock Today: BioMarin’s $14.50 Cash Buyout, Latest News, Analyst Forecasts, and What Comes Next (Dec. 21, 2025)

As of Sunday, December 21, 2025, Amicus Therapeutics, Inc. (Nasdaq: FOLD) has effectively become a “deal stock” — the market is now trading the shares primarily on the odds and timing of a takeover rather than on classic biotech catalysts. The reason is simple: on December 19, 2025, BioMarin Pharmaceutical announced a definitive agreement to acquire Amicus for $14.50 per…
21 December 2025
····
Amicus Therapeutics (FOLD) Stock Jumps on BioMarin’s $4.8B Buyout: Latest News, Forecasts, and Deal Analysis as of Dec. 20, 2025

Amicus Therapeutics (FOLD) Stock Jumps on BioMarin’s $4.8B Buyout: Latest News, Forecasts, and Deal Analysis as of Dec. 20, 2025

Amicus Therapeutics, Inc. (NASDAQ: FOLD) has become one of the most closely watched rare-disease stocks heading into the final stretch of 2025 after BioMarin Pharmaceutical announced a definitive agreement to acquire Amicus in an all-cash transaction valued at about $4.8 billion. The offer price—$14.50 per share in cash—instantly reset the “center of gravity” for FOLD shares and shifted investor focus…
21 December 2025
···
Amicus Therapeutics Stock (FOLD) Surges After $4.8B BioMarin Buyout: $14.50 Offer, Deal Timeline, Analyst Outlook (Dec. 20, 2025)

Amicus Therapeutics Stock (FOLD) Surges After $4.8B BioMarin Buyout: $14.50 Offer, Deal Timeline, Analyst Outlook (Dec. 20, 2025)

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is having the kind of week biotech traders both crave and fear: a sudden, definitive catalyst that snaps the stock to a new reality overnight. On Friday, December 19, shares jumped about 30% and hovered around $14.18, after BioMarin Pharmaceutical announced a $14.50-per-share all-cash acquisition valuing Amicus at roughly $4.8 billion. Reuters Because it’s a…
20 December 2025
···
Merck & Company, Inc. (MRK) Stock News and Forecasts: FDA Fast-Track Signals, BMO Upgrade, and a New Keytruda–Padcev Win (Dec. 18, 2025)

Merck & Company, Inc. (MRK) Stock News and Forecasts: FDA Fast-Track Signals, BMO Upgrade, and a New Keytruda–Padcev Win (Dec. 18, 2025)

December 18, 2025 — Merck & Company, Inc. (NYSE: MRK) is back in the spotlight for investors today as three threads converge: a fresh Wall Street upgrade tied to Merck’s post‑Keytruda strategy, a potentially meaningful FDA fast‑track development for two pipeline assets, and new Phase 3 momentum for the company’s blockbuster oncology franchise in earlier‑stage bladder cancer. Merck shares traded…
18 December 2025
····
Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility

Summit Therapeutics (SMMT) Stock on December 9, 2025: Trial Optimism Collides With High Risk, High Volatility

Summit Therapeutics Inc. (NASDAQ: SMMT) continues to trade like a classic high-beta biotech: big promises in lung cancer, plenty of red flags, and a stock price stuck near the lower end of its 52-week range while analysts project eye-popping upside. As of the latest US session on December 9, 2025, SMMT is trading around $17–18 per share, versus a 52-week…
9 December 2025
····
Moderna (MRNA) Stock on 8 December 2025: Institutional Tug‑of‑War, FDA Shockwaves and 2026–2030 Forecasts

Moderna (MRNA) Stock on 8 December 2025: Institutional Tug‑of‑War, FDA Shockwaves and 2026–2030 Forecasts

Published: 8 December 2025 – all data and news current to this date. This article is informational only and not investment advice. Key takeaways Where Moderna stock stands today As of 8 December 2025, Moderna shares trade around $27.70, roughly flat after a powerful rebound that saw the stock jump 8–9% on 5 December on heavy volume. StockInvest Over the…
8 December 2025
····
Regeneron (REGN) Stock on December 2, 2025: Outlook, Forecast and Key Catalysts After Gene‑Editing Deal

Regeneron (REGN) Stock on December 2, 2025: Outlook, Forecast and Key Catalysts After Gene‑Editing Deal

Regeneron stock snapshot on 2 December 2025 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is trading around $742 per share in late U.S. trading on December 2, 2025, after moving between roughly $731 and $749 during the session and opening close to $742. StockAnalysis Key valuation and trading metrics: Over the past month, REGN has rallied sharply. Zacks notes the stock has…
2 December 2025
··
Repare Therapeutics (RPTX) Soars on XenoTherapeutics Takeover Deal: Cash + CVR Offer, Analyst Downgrade and What to Watch on 17 November 2025

Repare Therapeutics (RPTX) Soars on XenoTherapeutics Takeover Deal: Cash + CVR Offer, Analyst Downgrade and What to Watch on 17 November 2025

Repare Therapeutics Inc. (NASDAQ: RPTX) is back in the spotlight today after investors digested last week’s surprise acquisition agreement with XenoTherapeutics, Inc., a Massachusetts-based non‑profit biotech. The stock is trading sharply higher and unusually active as the market prices in a mostly cash takeover and a complex contingent value right (CVR) structure that could unlock additional upside over the coming…
17 November 2025
····
Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson’s $3.05 Billion Halda Therapeutics Deal Signals New Oncology Push After Stelara Patent Cliff

Johnson & Johnson has struck a $3.05 billion cash deal to acquire Halda Therapeutics, a privately held cancer-drug developer based in New Haven, Connecticut, in one of 2025’s biggest oncology takeovers so far. Reuters The move deepens J&J’s bet on cancer medicines just as sales of its long‑time blockbuster psoriasis drug Stelara are being hit hard by a wave of…
17 November 2025
··
Korro Bio (KRRO) Stock Crashes as Novo Nordisk Pauses Pact, KRRO‑110 Disappoints and 34% Layoffs Extend Cash Runway – What Investors Need to Know Today

Korro Bio (KRRO) Stock Crashes as Novo Nordisk Pauses Pact, KRRO‑110 Disappoints and 34% Layoffs Extend Cash Runway – What Investors Need to Know Today

Korro Bio, Inc. (NASDAQ: KRRO) is at the center of one of biotech’s biggest shake‑ups of 2025. After releasing mixed early data from its lead RNA‑editing program, KRRO‑110, the company has announced deep layoffs, a strategic pivot in its pipeline and a 12‑month pause in its high‑profile collaboration with Novo Nordisk. The stock has responded with a brutal collapse. As…
13 November 2025
····
CorMedix (CRMD) Q3 2025: Net Income Hits $108.6M, FY25 Guidance Raised to $390–$410M — Nov 12, 2025

CorMedix (CRMD) Q3 2025: Net Income Hits $108.6M, FY25 Guidance Raised to $390–$410M — Nov 12, 2025

CorMedix Inc. (NASDAQ: CRMD) reported a profitable third quarter and lifted full‑year guidance today as momentum in DefenCath and contributions from the Melinta portfolio accelerated growth. TradingView What happened CorMedix said third‑quarter 2025 net revenue came in at $104.3 million (pro forma $130.8 million), fueled by higher‑than‑expected outpatient DefenCath utilization and partial‑quarter sales from the Melinta portfolio. The company posted…
12 November 2025
···
1 2 3 4

Stock Market Today

  • Soybeans Retreat from Early Gains as Export Data Shows Mixed Signals
    January 27, 2026, 1:25 AM EST. Soybean futures dropped 4 to 5 cents on Monday after initial overnight gains, with March contracts at $10.63 per bushel. The national average cash soybean price rose slightly to $9.93 1/4. Export inspections revealed shipments of 1.324 million metric tons last week, down 1.54% from the week before but up nearly 80% year-on-year. China remained the largest destination. Marketing year shipments have increased 37.5% year-on-year. However, recent export sales are 22% below last year, underperforming USDA projections. Speculative traders reduced net long positions by nearly 3,000 contracts, reflecting cautious sentiment. Brazil's harvest is progressing briskly with a crop estimate raised to 181 million metric tons. Soymeal futures fell $3.90 to $4.70, while soy oil futures inched higher, indicating mixed demand pressures across related commodities.
Go toTop